Document Detail


Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
MedLine Citation:
PMID:  23055147     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: This study confirmed diabetes and smoking as independent risk factors for ICC. A novel finding was that treatment with metformin was significantly associated with a 60% reduction in ICC risk in diabetic patients.
Authors:
Roongruedee Chaiteerakij; Ju Dong Yang; William S Harmsen; Seth W Slettedahl; Teresa A Mettler; Zachary S Fredericksen; W Ray Kim; Gregory J Gores; Rosebud O Roberts; Janet E Olson; Terry M Therneau; Lewis R Roberts
Related Documents :
24698737 - Nosocomial candida parapsilosis candidaemia: risk factors, antifungal susceptibility an...
23591257 - Does accelerated reproductive aging underlie premenopausal risk for cardiovascular dise...
24206627 - Prevalence and risk factors of pelvic pain.
24685257 - Assessment of the effect of iris colour and having children on 5-year risk of death aft...
23951177 - Epidemiology of brucellosis and q fever in linked human and animal populations in north...
22542707 - Social inequalities and gender differences in the experience of alcohol-related problems.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-12-12
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-06     Completed Date:  2013-04-04     Revised Date:  2014-02-28    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  648-55     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms / etiology
Case-Control Studies
Cholangiocarcinoma / etiology*,  prevention & control
Diabetes Complications / prevention & control
Diabetes Mellitus / drug therapy*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipidemias / drug therapy
Liver Neoplasms / etiology*,  prevention & control
Male
Metformin / therapeutic use*
Middle Aged
Obesity / complications
Regression Analysis
Risk Factors
Smoking / adverse effects
Grant Support
ID/Acronym/Agency:
CA100882/CA/NCI NIH HHS; CA128633/CA/NCI NIH HHS; CA15083/CA/NCI NIH HHS; CA165076/CA/NCI NIH HHS; P30 DK084567/DK/NIDDK NIH HHS; P30DK084567/DK/NIDDK NIH HHS; R01 CA165076/CA/NCI NIH HHS; R21 CA128633/CA/NCI NIH HHS; R56 CA100882/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9100L32L2N/Metformin
Comments/Corrections
Comment In:
Hepatology. 2013 Nov;58(5):1863   [PMID:  23564496 ]
Hepatology. 2013 Nov;58(5):1862-3   [PMID:  23609480 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Attention improves perceptual quality.
Next Document:  Four cases of possible human infections with Delftia lacustris.